Celularity Inc.
CELU
Rank in Stocks
#25649
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to... Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Share Price
$0.7597
Last synced: 2026-11-09
Market Cap
$24.65M
Change (1 day)
-0.05%
Change (1 year)
-55.83%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Celularity Inc. (CELU)
Category
Healthcare
Operating Margin for Celularity Inc. (CELU)
Operating Margin as of November 2026 TTM: -264.27%
According to Celularity Inc.'s latest financial reports, its current operating margin (TTM) is -264.27%. At the end of 2025 the company had an operating margin of -230.92%.
Operating Margin history for Celularity Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -264.27% | 14.44% |
| 2025 | -230.92% | 226.39% |
| 2024 | -70.75% | -91.62% |
| 2023 | -844.44% | 492.92% |
| 2022 | -142.42% | -72.14% |
| 2021 | -511.17% | -51.96% |
| 2020 | -1,064.05% | -14.81% |
| 2019 | -1,249.01% | 12,490,000.00% |
| 2018 | -0.01% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.15% |
US
|
|
| -149.01% | -99.44% |
US
|
|
| 25.57% | -100.10% |
AU
|
|
| 31.23% | -100.12% |
BE
|
|
| 29.35% | -100.11% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Celularity Inc.'s operating margin
What is Celularity Inc.'s operating margin?
Celularity Inc.'s operating margin is -264.27%, as of Nov 2026.
What was Celularity Inc.'s operating margin in 2025?
In 2025, Celularity Inc.'s operating margin was -230.92%, compared with -70.75% in 2024.
How has Celularity Inc.'s operating margin changed since 2020?
From 2020 to 2025, Celularity Inc.'s operating margin was highest in 2024 (-70.75%) and lowest in 2020 (-1,064.05%).
How does Celularity Inc.'s operating margin compare with similar companies?
Celularity Inc.'s operating margin (-264.27%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.